OPKO Health Inc represents a commitment to advancing patient care and creating innovative solutions in healthcare. With a focus on precision medicine, the company strives to improve diagnostic testing and develop therapeutic treatments across various disease areas. OPKO Health Inc values scientific excellence, collaboration, and continuous innovation to enhance patient outcomes. By leveraging cutting-edge technologies and expertise, the company aims to address unmet medical needs and make a positive impact on global healthcare. Through its dedication to research and development, OPKO Health Inc is dedicated to improving the quality of life for individuals worldwide.

OPKO Health Inc is primarily present in several countries and regions. These include the United States, where the company is headquartered in Miami, Florida. Additionally, OPKO Health Inc has a significant presence in Chile, where it operates a subsidiary known as OPKO Chile. The company also has operations and partnerships in Israel, Mexico, and Ireland. With its global presence, OPKO Health Inc continues to expand its reach and make advancements in the healthcare industry across various markets.

OPKO Health Inc has achieved several significant milestones. Some of these include the FDA approval of its RECORLEV™ (levoketoconazole) drug for the treatment of endogenous Cushing's syndrome, a rare hormonal disorder. The company also received FDA approval for its RAYALDEE® (calcifediol) extended-release capsules for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease. Furthermore, OPKO Health Inc has made advancements in its diagnostics segment through the development of proprietary molecular diagnostic tests for various diseases. These achievements showcase OPKO Health Inc's commitment to innovation and improving healthcare outcomes.

OPKO Health Inc is a biopharmaceutical and diagnostics company that focuses on developing diagnostic tests and pharmaceutical products for various medical conditions. Founded in 1991, the company has grown to become a leading player in the healthcare industry. OPKO Health Inc has a diverse portfolio of products and services, including point-of-care diagnostics, molecular diagnostics, and pharmaceuticals for the treatment of conditions such as prostate cancer, metabolic disorders, and ophthalmic diseases. With its strong emphasis on research and development, OPKO Health Inc remains committed to improving patient outcomes and providing innovative solutions in the field of healthcare.

Some of the main competitors of OPKO Health Inc in the market include companies such as AbbVie Inc, Thermo Fisher Scientific Inc, and Quest Diagnostics Incorporated.

OPKO Health Inc primarily operates in the biotechnology and pharmaceutical industries.

OPKO Health Inc's business model focuses on the discovery, development, and commercialization of innovative healthcare solutions. The company operates through two main segments: Pharmaceuticals and Diagnostics. In the Pharmaceuticals segment, OPKO develops and markets a range of specialty pharmaceutical products, with a particular focus on treating chronic diseases and conditions. The Diagnostics segment involves the development and distribution of a variety of diagnostic tests and technologies across multiple therapeutic areas. Through these segments, OPKO Health Inc aims to leverage its expertise and technologies to provide better healthcare solutions to patients around the world.

Коефициентът на цена спрямо печалбата (КЦП) на OPKO Health е -3,60.

Коефициентът на цена към оборот (KUV) на OPKO Health е 1,32.

AlleAktien качественият резултат за OPKO Health е 3/10.

очаквана OPKO Health оборотът е 718,12 млн. USD.

очаквана OPKO Health печалба е -262,81 млн. USD.

OPKO Health Inc is a diversified healthcare company focused on a wide range of diagnostic, pharmaceutical, and biotechnology products and services. The company was founded in 1991 and is headquartered in Miami, Florida. The business model of OPKO is to offer innovative diagnostic and therapeutic solutions for a variety of diseases. The company operates various business segments, including diagnostics and pharmaceuticals, biotechnology, and research and development. Diagnostics and Pharmaceuticals: OPKO is a leading provider of medical diagnostic tests, including PSA tests for prostate cancer, 4KScore for aggressive prostate cancer, and Claros 1 for rapid diagnosis of heart disease. The company also offers a wide range of pharmaceutical products for the treatment of diseases such as hemophilia, growth hormone deficiency, and low testosterone. Biotechnology: OPKO owns and operates a variety of biotechnology companies and related product lines. DemosRx produces and distributes drugs for ophthalmology and dermatology, while Bio-Reference Laboratories provides medical testing and services for physicians and clinics, supporting their patients through a wide range of pathology tests. The combination of these two diagnostic units is intended to provide hospitals with a more comprehensive second opinion in diagnosis, particularly for patients who benefit from second opinions, recognized expert opinions, or patients removed from Soliris. Research and Development: OPKO invests significant sums in research and development of new medical technologies and drugs. The company has research projects in the areas of oncology, ophthalmology, obstetrics and gynecology, neurology, and gastroenterology. Some of OPKO's key projects include the development of drugs for the treatment of Alzheimer's, autism, osteoporosis, and diabetes. OPKO Health Inc aims to offer innovative solutions to patients and medical professionals worldwide. The company builds on its position as a leading provider of diagnostic products and services and is committed to translating innovative research findings into new drugs and therapies. Overall, OPKO Health Inc is a leading provider of medical diagnostic tests, pharmaceutical products, and biotechnology solutions with the goal of improving the lives of patients worldwide.

OPKO Health разпределя дивидента от 0 USD на плащания годишно.

Дивидентата за OPKO Health в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на OPKO Health е US68375N1037.

WKN на OPKO Health е A0MUUJ.

Тикерът на OPKO Health е OPK.

През последните 12 месеца OPKO Health изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква OPKO Health да изплати дивиденда в размер на 0 USD.

Дивидентната доходност на OPKO Health в момента е .

OPKO Health изплаща дивидент на тримесечие. Той се разпределя в месеците .

OPKO Health платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 USD. Това съответства на дивидентна доходност от 0 %.

OPKO Health се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от OPKO Health на 8.07.2024 г. в размер на 0 USD, трябваше да притежавате акцията в портфейла си преди Ex-деня на 8.07.2024 г..

Последното дивидентно плащане беше извършено на 8.07.2024 г..

През година 2023 OPKO Health изплати 0 USD под формата на дивиденти.

Дивидентите от OPKO Health се изплащат в USD.